Posted by Michael Wonder on 14 Feb 2025
European Commission approves CSL's Andembry (garadacimab) for the prevention of recurrent attacks of hereditary angioedema
13 February 2025 - Supported by the Phase 3 VANGUARD trial, this marks the third regulatory approval for Andembry, which was also recently approved by Australia's TGA and the UK MHRA in January.
CSL today announced that the European Commission has approved Andembry (garadacimab), the first and only once monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema in adult and adolescent patients aged 12 years and older.
